Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Other Non-Current Liabilities (2020 - 2023)

Candel Therapeutics' Other Non-Current Liabilities history spans 4 years, with the latest figure at $433000.0 for Q3 2023.

  • For Q3 2023, Other Non-Current Liabilities fell 90.64% year-over-year to $433000.0; the TTM value through Sep 2023 reached $433000.0, down 90.64%, while the annual FY2022 figure was $1.9 million, 89.69% down from the prior year.
  • Other Non-Current Liabilities for Q3 2023 was $433000.0 at Candel Therapeutics, down from $1.0 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $27.4 million in Q3 2021 and bottomed at $433000.0 in Q3 2023.
  • The 4-year median for Other Non-Current Liabilities is $5.0 million (2022), against an average of $8.7 million.
  • The largest annual shift saw Other Non-Current Liabilities soared 167.19% in 2021 before it crashed 90.64% in 2023.
  • A 4-year view of Other Non-Current Liabilities shows it stood at $6.8 million in 2020, then skyrocketed by 167.19% to $18.3 million in 2021, then crashed by 89.69% to $1.9 million in 2022, then crashed by 76.99% to $433000.0 in 2023.
  • Per Business Quant, the three most recent readings for CADL's Other Non-Current Liabilities are $433000.0 (Q3 2023), $1.0 million (Q2 2023), and $1.2 million (Q1 2023).